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Abstract
Background: Hsp90 (heat shock protein90) is a chaperone protein essential for preserving and regulating the function 
of various cellular proteins. Elevated Hsp90 expression seems to be a trait of breast cancer and may be an integral part 
of the coping mechanisms that cancer cells exhibit vis-à-vis stress. This manuscript tries to examine the 
immunohistochemical expression of Hsp90 all along the continuum of breast ductal lesions encompassing ductal 
hyperplasia without atypia (DHWithoutA), atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS) and 
invasive ductal carcinoma (IDC).
Methods: Tissue specimens were taken from 30 patients with DHWithoutA, 31 patients with ADH, 51 with DCIS and 51 
with IDC. Immunohistochemical assessment of Hsp90 was performed both in the lesion and the adjacent normal 
breast ducts and lobules; the latter serving as control. Concerning Hsp90 assessment the percentage of positive cells 
and the intensity were separately analyzed. Subsequently, the Allred score was calculated. Post hoc analysis on the 
correlations between Hsp90 Allred score and possible predictors (grade, nodal status, tumor size, ER Allred score, PR 
Allred score, c-erbB-2 status and triple negative status) was conducted in IDC.
Results: Hsp90 exhibited mainly cytoplasmic immunoreactivity. Hsp90 Allred score exhibited an increasing trend 
along the continuum of breast ductal lesions (Spearman's rho = 0.169, p = 0.031). Compared to the adjacent normal 
ducts and lobules, no statistically significant differences were noted in DHwithoutA, ADH and DCIS. Hsp90 expression 
(intensity, positive cells, Allred score) was higher in IDC, compared to the adjacent normal tissue. Higher Hsp90 
expression was observed in grade 2/3 IDCs (borderline association) and tumors of larger size. At the univariable 
analysis, higher Hsp90 expression was associated with higher ER Allred score, PR Allred score and c-erbB-2 positivity in 
IDC. Triple-negative IDCs exhibited significantly lower Hsp90 expression. The multivariable logistic regression model 
revealed that between the three markers, solely ER Allred score and c-erbB-2 positivity were independently associated 
with higher Hsp90 expression in IDC.
Conclusion: The above point to significant variability in Hsp90 expression with significant implications upon the 
effectiveness and limitations of anti-Hsp90 drugs.
Background
Hsp90 (heat shock protein 90, also known as HSPC1
according to the most recent nomenclature assigned by
the HUGO Gene Nomenclature Committee [1]) is a
chaperone protein essential for preserving and regulating
the function of various cellular proteins. Hsp90 mediates
its actions through the formation of discrete subcom-
plexes, each containing proteins-cochaperones that assist
protein folding and refolding during stress, protein trans-
port and degradation [2-4]. Hsp90 interacts with a num-
ber of protein-cornerstones in breast carcinogenesis.
Hsp90 counterparts include estrogen receptors (ER), p53
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protein, hypoxia-induced transcription factor HIF-
1alpha, protein kinase Akt, Raf-1 MAP kinase and a vari-
ety of receptor tyrosine kinases, such as erbB2 (reviewed
in [5]).
Elevated Hsp90 expression seems to be a trait of breast
cancer and may be an integral part of the coping mecha-
nisms that cancer cells exhibit vis-à-vis stress [6-8]. As a
result clinical implications of Hsp90 expression have
emerged; Hsp90 upregulation may be a sign of unfavour-
able prognosis [9]. Another clinical implication concerns
the pharmacological inhibition of Hsps [10-14]. Indeed,
positive results have appeared in the literature concern-
ing 17-allylamino, 17-demethoxygeldanamycin (17-
AAG), the first Hsp90 inhibitor having entered clinical
trials [5,15].
Previous studies have appeared concerning IDC [9,16],
where positive association between Hsp90 expression
and grade, nodal positivity, tumour size, ER, c-erbB-2 and
decreased survival have been documented [9]. However,
Hsp90 expression in precursor (ADH) and preinvasive
lesions (DCIS) have not yet been studied. Precursor and
preinvasive lesions exhibit a distinct immunohistochemi-
cal profile regarding established markers such as ER, pro-
gesterone receptors (PR), c-erbB-2 etc [17]. It seems thus
fairly rational to postulate that precursor and preinvasive
lesions may also exhibit a distinct profile of Hsp90
expression. Interestingly, the sole study to focus exclu-
sively on precursor lesions concerns the lobular series
[18], where Hsp90 downregulation became unexpectedly
evident.
Given the above, this is the first study to examine the
immunohistochemical expression of Hsp90 all along the
continuum of breast ductal lesions encompassing ductal
hyperplasia without atypia (DHWithoutA), ADH, DCIS
and IDC. In addition, a post hoc sub-analysis in IDC
incorporating ER, PR, c-erbB-2 (integrated as triple nega-
tive status and assessed through a multivariable
approach, for the first time to our knowledge), tumor
size, grade and nodal status is presented.
Methods
This study included formalin-fixed, paraffin-embedded
tissue specimens from 30 patients with DHWithoutA, 31
patients with ADH, 51 with DCIS and 51 patients with
IDC. The patients' age at operation ranged between 31
and 78 (median age: 51 years). The diagnosis of the
lesions was established by vacuum-assisted breast biopsy,
excisional breast biopsy, lumpectomy and modified radi-
cal mastectomy. All lesions were independent i.e., no
DHWithoutA, ADH, DCIS lesions coexisted with inva-
sive carcinomas. Cases coexisting with lobular neoplasia
and infiltrating lobular carcinoma were also excluded.
Hsp90 was immunohistochemically detected using the
mouse monoclonal antibody Hsp90 (clone JPB24, NCL-
Hsp90, Novocastra supplied by Menarini). The dilution
was 1:500 and the incubation time was equal to 18 h (at
4°C). The visualization was performed using an avidin-
biotin detection system m (Envision, Dako). Antigen
retrieval was achieved in 0.01 M citrate buffer (pH = 6.0)
at 85°C for 15 min. Immunohistochemical assessment of
Hsp90 was performed both in the lesion and the adjacent
normal breast ducts and lobules; the latter serving as con-
trol. Negative controls were assessed by omitting the pri-
mary antibody.
Concerning Hsp90 assessment: i) the percentage of
positive cells and ii) the intensity was separately analyzed.
Subsequently, the Allred score was appropriately calcu-
lated summing the proportion score (represented by the
estimated proportion of positive cells), as well as the
intensity score (represented by the average intensity of
positive cells) [19].
For immunohistochemistry (IHC), the following anti-
bodies were used: PR (636, Dako), ER (ID5, Dako) and c-
erbB-2 (CB11, Novocastra™). Sections (4 μm thick) cut
from formalin-fixed paraffin embedded tissue were used.
After deparaffinization in xylene and hydration in graded
ethanol solutions, the sections of IDC tissue were sub-
jected to pretreatment in order to enhance antigen
retrieval. The EnVision + System-HRP (DAB) (DakoCyto-
mation, Glostrup, Danemark) was used with primary
antibodies against the following antigens: PR, ER and c-
erbB-2. Immunohistochemistry was performed accord-
ing to the protocols provided by the manufacturer. Con-
cerning the immunohistochemical expression of ER and
PR, both the intensity (negative, 1+ to 3+) and percentage
of immunopositive cells were evaluated. Subsequently,
the Allred score was calculated [19].
The expression of c-erbB-2 was assessed as follows: i)
negative, when no staining was documented or when
membrane staining was present in less than 10% of tumor
cells, ii) weak staining (+), when partial membrane stain-
ing was documented in more than 10% of tumor cells, iii)
moderate staining (++) when weak/moderate complete
membrane staining was present in more than 10% of
tumor cells and iv) strong staining when strong, complete
membrane staining was observed in more than 10% of
tumor cells. Cases with negative and weak c-erbB-2 stain-
ing were considered as negative, whereas cases with
strong c-erbB-2 staining were considered as positive. In
cases with moderate staining, CISH (chromogenic in situ
hybridization) was performed; subsequently these cases
were considered as negative or positive. The ready-to-use
Spot Light HER2/neu DNA Probe (Zymed/InVitrogen,
S a n  F r a n s i s c o ,  U S A )  w a s  u s e d  f o r  C I S H ;  t h i s  d i g o x y -
genin-labeled probe is located on 17q12-21 and covers
the entire gene area.
In all cases, ten fields (×40 magnification) were assessed
and a minimum of 100 cells were evaluated in the desig-Zagouri et al. BMC Cancer 2010, 10:353
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nated areas, so as to evaluate the lesion as a whole. The
immunohistochemical evaluation was performed inde-
pendently by two consultant histopathologists (AN and
AL).
The intensity was treated as an ordinal variable-score
(0: negative, low: 1, moderate: 2, high: 3); Allred scores
(ER, PR, Hsp90) have been treated as ordinal variables,
whereas tumor size has been treated as a continuous vari-
able. Due to deviation from the normal distribution, non-
parametric statistics were chosen. The analysis included
two steps: i) comparison of Hsp90 expression (Hsp90
intensity, positive cells (%), Allred score) in the lesions vs.
the adjacent normal ducts and lobules. Where appropri-
ate, power calculations were performed. ii) A test for sig-
nificance of the Hsp90 trend along the continuum of
lesions. The correlation between Hsp90 Allred score in
the lesion and the severity of the lesion (1:DHWithoutA,
2:ADH, 3:DCIS, 4:IDC) was evaluated; Spearman's rank
correlation coefficient was appropriately implemented.
iii) Post hoc analysis on the correlations between Hsp90
Allred score and possible predictors (grade, nodal status,
tumor size, ER Allred score, PR Allred score, c -erbB-2
status and triple negative status) was conducted in IDC.
Once again non-parametric statistics were performed
under the light of deviation from normality and limited
sample size. In addition, concerning the three immuno-
histochemical markers, multivariable logistic regression
was performed as follows: Hsp90 Allred score was con-
verted to a binary dependent variable [0: Hsp90 Allred
score ≤ 7 (n = 28) and 1: Hsp90 Allred score = 8 (n = 23),
as the median Hsp90 Allred score was equal to 7],
whereas ER Allred score (continuous variable), PR Allred
score (continuous variable) and c-erbB-2 status (positive
vs. negative) were the independent variables.
Results of borderline statistical significance (0.1 < p <
0.05) have also been reported, given that they might
become significant in the context of a larger sample size.
Statistical analysis was performed with STATA 8.0 statis-
tical software (Stata Corporation, College Station, TX,
USA).
Informed consent was obtained by all participants in
this study. This study has been approved by the local Eth-
ics Committee, in compliance to the Helsinki Declara-
tion.
Results
Hsp90 exhibited mainly cytoplasmic immunoreactivity in
epithelial cells of normal breast (ducts and lobules) (fig-
ure 1), ADH (figure 2), DCIS (figure 3) and IDC (figure 4,
5). Some epithelial cells also showed nuclear staining;
nevertheless, all the DHWithoutA, ADH, DCIS and IDC
foci mainly presented with a positive cytoplasmic immu-
noreaction for Hsp90. The percentage of these positive
cells and the staining intensity were evaluated.
The percentage of Hsp90 positive cells, the intensity of
Hsp90 staining, as well as the Allred score are presented
in detail in Table 1. Compared to the adjacent normal
ducts and lobules, no statistically significant differences
were noted in DHWithoutA and ADH. Despite the
numerical superiority in DCIS, the discrepancies failed to
reach statistical significance. Indeed, given the present
results, and assuming a type I error equal to 0.1 (thresh-
old of borderline statistical significance), the study power
was equal to 0.21 i.e. 21%. Given the present results and
under the same assumptions, 466 cases of DCIS would be
needed to achieve the optimal study power of 80%. Hsp90
expression (intensity, positive cells, Allred score) was
higher in IDC, compared to the normal adjacent ducts
and lobules (Table 1). Hsp90 Allred score exhibited an
increasing trend along the continuum of breast ductal
lesions (Spearman's rho = 0.169, p = 0.031).
Figure 1 Moderate Hsp90 immunostaining in epithelial cells of 
normal breast (ducts and lobules) (×200).
Figure 2 Moderate expression of Hsp90 in atypical ductal hyper-
plasia (×400).Zagouri et al. BMC Cancer 2010, 10:353
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In the subanalysis concerning clinicopathological fea-
tures (Table 2), higher Hsp90 expression was observed in
grade 2/3 IDCs (borderline association), and larger tumor
size. Table 2 presents the results in detail; median tumor
size was equal to 2 cm and the dichotomization to cases <
median and ≥median are provided for purely descriptive
purposes, given that tumor size was treated as a continu-
ous variable.
Table 3 presents the associations of Hsp90 Allred score
with the immunohistochemical markers (figure 6, 7, 8).
At the univariable analysis, higher Hsp90 expression was
associated with higher ER Allred score (median: 7), PR
Allred score (median:4) and c-erbB-2 positivity. Interest-
ingly, triple-negative IDCs exhibited significantly lower
Hsp90 expression (of note, the nodal status of triple-neg-
ative IDCs did not differ from the remaining tumors, p =
0.391, Mann-Whitney-Wilcoxon test for independent
samples [MWW]) present It is worth mentioning that ER
Allred score was positively associated with PR Allred
score (Spearman's rho = 0.522, p = 0.0001), whereas no
significant association existed between ER Allred score
and c-erbB-2 status (p = 0.849, MWW) nor between PR
Allred score and c-erbB-2 status (p = 0.610, MWW).
The multivariable logistic regression model revealed
that between the three markers, solely ER Allred score
(OR = 1.29, 95%CI: 0.99-1.66) and c-erbB-2 positivity
were independently associated with higher Hsp90 expres-
sion (OR = 1.85, 95%CI: 1.14-3.02).
Discussion
This study is the first to investigate Hsp90 expression in
precursor and preinvasive lesions. Noticeably, ADH did
not exhibit a statistically significant difference whereas
the numerical difference pointing to Hsp90 upregulation
in DCIS failed to reach statistical significance. This find-
ing may imply that the precursor context may not entail
the cellular stress present in invasive cancer [18]. Conse-
quently, as an integral part of the stress response, Hsp90
per se appears not to have been triggered early. Neverthe-
less, the steady numerical increase in Hsp90 Allred score
along the ductal continuum may point to a simultaneous
unde r lying  incr ease  in c e l lula r st r es s, as  we ll  as  t o t he
multifaceted role mediated by Hsp90 in regulating the
stability and function of many oncogenic and anti-onco-
genic proteins, such as (ER), p53 protein, hypoxia-
induced transcription factor HIF-1alpha, protein kinase
Akt, Raf-1 MAP kinase and a variety of receptor tyrosine
kinases, such as erbB2 [3-5].
At the end of the continuum, the gradual increase in
Hsp90 expression reached statistical significance; Allred
score and both its components (intensity and percentage
of positive cells) were increased in IDC. Within the IDC
group a variety of inherent tumour features seemed to
Figure 3 In situ ductal carcinoma with moderate expression of 
Hsp90 (×200).
Figure 4 Intense expression of Hsp90 in invasive ductal carcino-
ma of the breast (×200).
Figure 5 Both the percentage and the staining intensity are in-
creased in invasive ductal carcinoma in comparison with the nor-
mal ductile (×200).Zagouri et al. BMC Cancer 2010, 10:353
http://www.biomedcentral.com/1471-2407/10/353
Page 5 of 9
correlate with higher Hsp90 expression. Tumors of larger
size also presented with more pronounced Hsp90 upreg-
ulation, which is in accordance with previous reports [9]
and seems to reflect the stress-related events in rapidly
proliferating hypoxic (due to their size) tumours. Con-
cerning tumor grade, however, the positive association
with Hsp90 immunostaining should be interpreted with
caution, given its borderline nature, as well as the small
number of grade 1 IDCs in our sample.
Concerning immunohistochemical markers, this is the
first study to adopt a multivariable approach. The univar-
iable analysis shows that the higher Hsp90 expression was
associated with higher ER, PR expression and c-erbB-2
positivity. The association between PR and Hsp90 expres-
sion is in line with previous studies [20,21]; nevertheless,
given that ER and PR were closely associated in our study
sample, as expected [22], this represented a secondary
indirect association. As a result, the multivariable
approach reported that the sole immunohistochemical
markers independently associated with elevated Hsp90
expression are ER and c-erbB-2. This confirms and adds
to the validity of the findings reported by Pick et al. [9],
who however only performed a univariable analysis.
Commenting further on the immunohistochemical
profile, significantly decreased Hsp90 expression has
been observed in triple-negative tumours. This is in
accordance with the study by Sun et al [16] and may seem
fairly rational as Hsp90 is associated with ER and c-erbB-
2 expression. Our study highlights a paradox; on the one
hand elevated Hsp90 has been suggested as a poor prog-
nostic factor [9], whilst on the other hand triple-negative
tumors, exhibiting decreased Hsp90 expression, are asso-
ciated with poor prognosis (reviewed in [23]). Under the
light of the above, the application of Hsp90 as a poor
prognostic factor in all types of breast cancer may be
worth interpreting with caution; accordingly, no statisti-
cally significant association emerged between nodal sta-
tus and Hsp90 expression in our study, contrary to the
report by Pick et al [9]. Nevertheless, the present study is
not a prognosis study and thus no further firm conclu-
Table 1: Hsp90 expression in ADH, DCIS and IDC
Adjacent normal ducts and lobules DHwithoutA (n = 30) pa
Hsp90 intensity (score) 2.27 ± 0.58 2.33 ± 0.55 0.593
Hsp90 positive cells (%) 70.7 ± 9.44 71.7 ± 12.3 0.664
Hsp90 Allred score 7.00 ± 0.87 7.00 ± 0.79 0.896
Adjacent normal ducts and lobules ADH (n = 31) pa
Hsp90 intensity (score) 2.26 ± 0.63 2.39 ± 0.62 0.346
Hsp90 positive cells (%) 69.4 ± 10.3 72.3 ± 14.7 0.195
Hsp90 Allred score 6.97 ± 0.98 7.00 ± 0.97 0.660
Adjacent normal ducts and lobules DCIS (n = 51) pa
Hsp90 intensity (score) 2.29 ± 0.61 2.43 ± 0.67 0.285
Hsp90 positive cells (%) 69.0 ± 8.5 71.0 ± 14.9 0.298
Hsp90 Allred score 7.00 ± 0.77 7.14 ± 0.94 0.360
Adjacent normal ducts and lobules IDC (n = 51) pa
Hsp90 intensity (score) 2.20 ± 0.63 2.49 ± 0.54 0.018
Hsp90 positive cells (%) 68.8 ± 9.7 74.3 ± 14.9 0.004
Hsp90 Allred score 6.90 ± 0.78 7.33 ± 0.77 0.002
ap-value derived from Wilcoxon matched-pairs signed-ranks testZagouri et al. BMC Cancer 2010, 10:353
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Page 6 of 9
sions can be drawn on this important field. Future studies
focusing exclusively on triple negative tumors seem desir-
able, as triple-negative tumors were solely 9 (17.7%) of all
IDCs in this study.
The evaluation of Hsp90 expression all along the ductal
continuum, presented herein, may have particular clinical
significance. Firstly, given that ADH did not exhibit
marked Hsp90 upregulation, the potential involvement of
anti-Hsp90 drugs as chemoprevention agents may not be
supported. In addition, given the associations between
Hsp90, ER and c-erbB-2, it seems desirable that the
effects of Hsp90 targeting drugs should be evaluated sep-
arately on different immunohistochemical types of IDC,
since their effectiveness may vary accordingly.
I n  o u r  c a s e s ,  s o m e  e p i t h e l i a l  c e l l s  o f  D H W i t h o u t A ,
ADH, DCIS and IDC showed scarce nuclear Hsp90 local-
ization. It should be declared that nuclear staining was
not taken into account at the calculation of Allred score,
as the latter was based exclusively on cytoplasmic Hsp90
staining. At any case, the significance of nuclear Hsp90
expression remains elusive, as some studies have not doc-
umented any nuclear Hsp90 expression in invasive ductal
carcinomas [9], whereas other researchers have [24].
Other researchers have correlated nuclear Hsp90 staining
with MHC class I expression in invasive breast carcino-
mas [25].
Concerning the limitations of this study, a number of
statistical points should be noted. Firstly, although this
study comprises the whole spectrum of ductal carcino-
Table 2: Subanalysis in IDC cases: clinicopathological variables
Variables N (%) Hsp90 Allred score in IDC p
Grade 0.061MWW
Grade 1 3 (5.9%) 6.67 ± 0.58
Grade 2 & 3 48 (94.1%) 7.38 ± 0.76
Nodal status 0.392S
N0 29 (56.9%) 7.28 ± 0.84
N1 13 (25.5%) 7.23 ± 0.73
N2 3 (5.9%) 7.67 ± 0.58
N3 6 (11.7%) 7.67 ± 0.52
Tumor size§ 0.033S
< median 20 (39.2%) 7.10 ± 0.97
≥median 31 (60.8%) 7.48 ± 0.57
MWWp-value derived from Mann-Whitney-Wilcoxon test for independent samples; Sp-value derived from Spearman's rank correlation 
coefficient; § tumor size has been treated as a continuous variable and thus the two subcategories serve purely descriptive purposes
Figure 6 ER strong intensity in invasive ductal carcinoma of the 
breast (×50).
Figure 7 PR strong intensity in invasive ductal carcinoma of the 
breast (×50).Zagouri et al. BMC Cancer 2010, 10:353
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genesis, the lack of power may have inhibited the docu-
mentation of significant associations; for instance
numerical discrepancies concerning DCIS may become
significant in larger comparative studies (approximately
500 DCIS cases). Moreover, the limited sample size did
not permit the performance of a multivariable analysis
including both clinicopathological and immunohis-
tochemical features, as the number of observations per
cell was not sufficient. Nevertheless, this study is the first
to adopt a multivariable assessment of Hsp90 predictors.
On the other hand, despite the relatively small sample
size, significant associations, such as the ER/Hsp90 and c-
erbB-2/Hsp90 interplay, have emerged and persisted at
the multivariable approach; this may point to their repro-
ducibility in larger samples. Nevertheless, further studies
with larger number of patients are warranted.
Other limitations of this study pertain to the method
performed (i.e., immunohistochemistry); the lack of an
Figure 8 c-erbB2 no membranous staining in invasive ductal car-
cinoma of the breast (×400).
Table 3: Subanalysis in IDC cases: immunohistochemical variables
Univariable analysis
Variables N (%) Hsp90 Allred score p
Triple-negative status§ 0.0004MWW
Triple-negative 9 (17.7%) 6.44 ± 1.01
Non-triple-negative 42 (82.3%) 7.52 ± 0.55
ER Allred score† 0.004S
< median 23 (45.1%) 7.04 ± 0.93
≥median 28 (54.9%) 7.57 ± 0.50
PR Allred score† 0.020S
< median 21 (41.2%) 6.95 ± 0.86
≥median 30 (58.8%) 7.60 ± 0.56
c-erbB-2 status 0.011MWW
Negative 29 (56.9%) 7.10 ± 0.86
Positive 22 (43.1%) 7.64 ± 0.49
Multivariable analysis
Variables Category or increment OR (95% CI) p
ER Allred score 1 point increase‡ 1.29 (0.99-1.66) 0.055
PR Allred score 1 point increase 1.18 (0.92-1.51) 0.195
c-erbB-2 status Positive vs. negative 1.85 (1.14-3.02) 0.013
MWWp-value derived from Mann-Whitney-Wilcoxon test for independent samples; Sp-value derived from Spearman's rank correlation 
coefficient; § not included in the multivariable analysis, as it integrates all three components (ER, PR, c-erbB-2); †ER Allred score, PR Allred score 
have been treated as continuous variables and thus the subcategories serve purely descriptive purposes ‡practical interpretation: increase in 
Allred score by one unit predicts OR = 1.29.Zagouri et al. BMC Cancer 2010, 10:353
http://www.biomedcentral.com/1471-2407/10/353
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automated quantitative procedure may have clouded
some associations. To ensure the objectivity of the assess-
ment, the percentage and intensity were assigned by two
independent pathologists blind to one another's results;
however, the need of additional verification of the present
results through Western blot should be declared. More-
over, all comparisons have been made versus the adjacent
normal ducts and lobules, as previously described [18]; it
would be of interest to verify the present results also on
normal glands taken for example from reduction mam-
moplasties or adjacent to fibroadenomas. In addition,
future studies should examine whether the findings of the
subanalysis on IDC (i.e., those implicating ER, PR and c-
erb-B2) are reproducible in DHWithoutA, ADH or DCIS;
data on these subpopulations were not available in this
study. Finally, reporting the survival would yield addi-
tional information concerning the clinical significance of
Hsp90 expression; the design of this retrospective study
did not include follow-up for survival analysis.
Conclusion
In conclusion, DHWithoutA, ADH and DCIS do not
exhibit marked Hsp90 upregulation, while IDC present
with elevated Hsp90 expression. Within IDC, a higher
grade, larger tumor size, higher ER expression and c-
erbB-2 positivity correlated with higher Hsp90 expres-
sion. Noticeably, triple-negative tumours exhibited
decreased Hsp90 expression. The above point to signifi-
cant variability in Hsp90 expression with significant
implications upon the effectiveness and limitations of
anti-Hsp90 drugs.
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